Bharat Immunologicals & Biologicals (BOM:524663) COGS-to-Revenue : 0.00 (As of Sep. 2023)

View and export this data going back to 2000. Start your Free Trial

What is Bharat Immunologicals & Biologicals COGS-to-Revenue?

Bharat Immunologicals & Biologicals's Cost of Goods Sold for the three months ended in Sep. 2023 was ₹0.00 Mil. Its Revenue for the three months ended in Sep. 2023 was ₹0.00 Mil.

Bharat Immunologicals & Biologicals's COGS to Revenue for the three months ended in Sep. 2023 was 0.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Bharat Immunologicals & Biologicals's Gross Margin % for the three months ended in Sep. 2023 was N/A%.

Bharat Immunologicals & Biologicals COGS-to-Revenue Historical Data

The historical data trend for Bharat Immunologicals & Biologicals's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bharat Immunologicals & Biologicals COGS-to-Revenue Chart

Bharat Immunologicals & Biologicals Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

COGS-to-Revenue

Get a 7-Day Free Trial

0.95

0.93

1.04

0.84

0.95

Bharat Immunologicals & Biologicals Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
COGS-to-Revenue	Get a 7-Day Free Trial															0.92	-	1.45	-	-

Bharat Immunologicals & Biologicals COGS-to-Revenue Calculation

Bharat Immunologicals & Biologicals's COGS to Revenue for the fiscal year that ended in Mar. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	422.083	/	446.091
	=	0.95

Bharat Immunologicals & Biologicals's COGS to Revenue for the quarter that ended in Sep. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	0
	=

Bharat Immunologicals & Biologicals (BOM:524663) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Bharat Immunologicals & Biologicals's Gross Margin % for the three months ended in Sep. 2023 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	0 / 0
	=	N/A %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Bharat Immunologicals & Biologicals COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Bharat Immunologicals & Biologicals's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Bharat Immunologicals & Biologicals (BOM:524663) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bharat Immunologicals & Biologicals Corp Ltd (BOM:524663) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

Village Chola, BIBCOL, OPV Plant, Bulandshahar, UP, IND, 203203

Website

http://www.bibcol.sciencecentral.in

Bharat Immunologicals & Biologicals Corp Ltd is an India-based biotechnology company. It primarily manufactures Oral polio vaccines. In addition, the company also manufactures zinc tablets, diarrhea management kits, and Ready to Use Therapeutic Food (RUTF). It also manufactures nutraceuticals and biological products for the treatment of health deficiencies and disorders. The firm is organized into three segments: Oral Polio Vaccine, Zinc Tablets, and BIB VIT, BIBSANIT. The group principally operates in India and generates the majority of its revenue from sales of Oral polio vaccines.

Bharat Immunologicals & Biologicals (BOM:524663) Headlines

No Headlines